Laura Mahecha
Director of Agrochemicals, Chemicals and Materials
A conversation with Laura Mahecha
Q1: People often describe U.S. IVM as a “growth market.” Is that accurate?
Not exactly. IVM is best understood as a mature core wrapped around a few genuinely expanding pockets, not a single growth story. Estimates range from 1–3% to 4–5% CAGR, and that spread reflects real structural differences between segments, not forecasting noise. The compliance-driven core (utilities, roadways, railways, pipelines) behaves very differently from niches like aquatics.
What this means for your portfolio: A single blended growth number will mislead planning. Model segment-by-segment, or you risk over-investing in a “growing” market that’s actually flat.
Q2: If demand is mandated, doesn’t that guarantee a stable market?
Stable in dollars, maybe. Rights-of-way vegetation management isn’t discretionary — operators must maintain cleared corridors, so budgets hold steady. But when prices rise faster than budgets, the same dollars buy products that are applied to less treated area. The market can look flat or growing in value while losing ground in acres and miles treated.
What this means for your portfolio: Volume-based revenue may be eroding even where your dollar sales look healthy. Track treated-area share, not just value share, to see real trajectory.
Q3: What’s driving pricing?
Herbicide and algaecide pricing is up an estimated 10–20% over three years, caused by tariffs on imported actives, packaging and supply chain inflation, and cost pass-through. Meanwhile generic competition, especially from the U.S. and Mexican markets, is pushing prices down on older off-patent actives.
What this means for your portfolio: If revenue growth is price-led on legacy actives, it’s fragile. Generic entry can reverse pricing quickly, and margin defense now depends on differentiated or patent-protected chemistry.
Q4: Which segments should suppliers actually be watching?
Rangeland and pastureland is the largest market segment, but the most weather-exposed — drought directly suppresses demand. Utilities and roadways are stable and mandate-driven; forestry is a stable, mature contributor. Railroads are also mandate-driven, with vegetation control required along tracks for safety, to avoid delays and derailments. The standout is aquatics, which is outpacing the market. Algaecide demand in particular is growing faster than herbicides on the back of invasive species and cyanobacteria concerns.
What this means for your portfolio: Heavy concentration in rangeland ties performance to weather. Aquatics is where under-recognized upside sits; it’s worth assessing whether your portfolio is positioned there.
Q5: What makes aquatics the segment to watch?
Aquatics is currently a small segment, but it behaves unlike any other in IVM. Growth is outpacing the rest of the market, driven by invasive species pressure, water quality concerns, and rising public and regulatory attention to lake and waterway management. Algaecide demand in particular is growing faster than herbicide demand, reflecting mounting concern over toxic cyanobacteria blooms. What makes it structurally attractive is that recurring treatment demand is effectively guaranteed — eradication of aquatic invasives is rarely achievable at scale, so the work is never really “done.”
What this means for your portfolio: Aquatics offers something the mandate-driven core doesn’t, genuine volume growth plus recurring, non-discretionary demand. A portfolio with little or no aquatics exposure is sitting out the segment most likely to expand.
Q6: Is glyphosate being replaced?
No. Glyphosate remains the largest active ingredient by volume, broad-spectrum efficacy and low cost keep it entrenched. What’s happening is a structural shift toward lower use-rate, environmentally favorable chemistries displacing legacy actives from the 1940s–1960s, driven by efficacy and regulatory durability.
What this means for your portfolio: Don’t read glyphosate’s staying power as license to stand still. Share is migrating to newer low-rate actives; portfolios anchored to legacy single molecules are most exposed.
Q7: How significant is weed resistance?
Resistance is expanding, creating pressure for new modes of action, but bringing a new active to market takes five to ten years and major capital, so a meaningfully expanded pipeline is unlikely within five years. The market will largely manage resistance with its existing toolkit via formulation optimization and program design.
What this means for your portfolio: Near-term advantage comes from formulation and program design, not new molecules. Suppliers who help customers solve resistance with today’s chemistry will defend share.
Q8: What about the regulatory environment?
Regulatory complexity is increasing, particularly for aquatic and other environmentally sensitive uses. Federal registration remains based on active-ingredient-specific risk assessment under FIFRA, while state registration requirements, aquatic-use permitting, and emerging scrutiny of fluorinated chemistries can create additional jurisdiction-specific constraints. As a result, regulatory exposure increasingly needs to be assessed by both active ingredient and geography.
What this means for your portfolio: Regulatory exposure is increasingly an asset-specific risk. Mapping active ingredients against federal re-evaluation, state restrictions, aquatic-use requirements, and other emerging regulatory scrutiny can help identify potential risks to future portfolio value.
Q9: Will technology like drones enhance market growth?
Technology changes how vegetation is managed, not how much is spent. GPS/satellite tracking is already standard. Drones are advancing toward commercial scale but function as a substitute delivery mechanism, not a volume driver — they may cut costs and open access-constrained areas without growing total treated area. Biological and non-chemical alternatives still have no meaningful industrial-scale traction.
What this means for your portfolio: Don’t expect precision tech or biologicals to expand your addressable volume. The winning play is products that perform reliably at lower use rates within precision-enabled programs.
Q10: What’s your outlook — and what separates the winners?
The core segments stay budget-capped with limited volume upside, there aren’t significant new corridor miles being built. Growth concentrates in aquatics, where recurring treatment is effectively guaranteed since eradication of aquatic invasives is rarely achievable at scale. Forestry also deserves attention: vegetation and forest management is increasingly crucial to preventing the kind of devastating wildfires seen recently in California and Canada. Low use-rate, differentiated chemistries will keep gaining share. The clearest risks are regulatory: withdrawals, generic pressure, accelerating resistance, and weather disruption.
What this means for your portfolio: In a structurally constrained market, share gains come from diversification into the chemistries and segments gaining spend. That’s what will separate suppliers that gain share from those that merely hold.
Kline’s Industrial Vegetation Management Market for Pesticides: U.S. study, now in its 25th edition, quantifies where spend is actually moving across segments, chemistries and suppliers — based on field research with approximately 600 end users.
Further Readings
